Wegener Granulomatosis: Case Report and Brief Literature Review

References

1. ↵
   Lie JT. Illustrated histologic classification criteria for selected vasculitis syndromes. Arthritis Rheum 1990; 33: 1074–87.

   OpenUrlPubMedWeb of Science
2. ↵
   Hewins P, Tervaert JW, Savage CO, Kallenberg CG. Is Wegener’s granulomatosis an autoimmune disease? Curr Opin Rheumatol 2000; 12: 3–10.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   Watts RA. Wegener’s granulomatosis: unusual presentations. Hosp Med 2000; 61: 250–3.

   OpenUrlPubMed
4. ↵
   Gross WL. Antineutrophil cytoplasmic autoantibody testing in vasculitides. Rheum Dis Clin North Am 1995; 21: 987–1011.

   OpenUrlPubMedWeb of Science
5. ↵
   Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488–98.
6. ↵
   Schmacher HR, Klippel JH, Koopman WJ, editors. Primer on the rheumatic disease. Atlanta: Arthritis Foundation; 1993. p. 136–48.
7. ↵
   Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76–85.
8. ↵
   Fauci AS, Wolff SM. Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973; 52: 535–61.

   OpenUrlCrossRefPubMed
9. ↵
   Anderson G, Coles ET, Crane M, et al. Wegener’s granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Scociety Research Committee. Q J Med 1992; 83: 427–38.
10. ↵
    Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA. Ocular complications of Wegener’s granulomatosis. Ophthalmology 1983; 90: 279–90.

    OpenUrlPubMedWeb of Science
11. ↵
    Haynes BF, Fishman ML, Fauci AS, Wolff SM. The ocular manifestations of Wegener’s granulomatosis. Fifteen years experience and review of literature. Am J Med 1977; 63: 131–41.

    OpenUrlCrossRefPubMedWeb of Science
12. Klinger H. Grenzforman der periarteritis nodosa. Frankfurt Z Pathol 1931; 42: 455–80.

    OpenUrl
13. De Oreo GA. Wegener’s granulomatosis. Arch Dermatol 1960; 81: 169–74.
14. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s Granulomatosis). Br Med J 1958; 2: 265–70.
15. Aymard B, Bigard MA, Thompson H, Schmutz JL, Finet JF, Borrelly J. Perianal ulcer: an unusual presentation of Wegener’s granulomatosis. Report of a case. Dis Colon Rectum 1990; 33: 427–30.

    OpenUrlPubMed
16. Wilson RT, Dean PJ, Upshaw JD, Wruble LD. Endoscopic appearance of Wegener’s granulomatosis involving the colon. Gastrointest Endosc 1987; 33: 388–9.

    OpenUrlPubMed
17. Grant SC, Levy RD, Venning MC, Ward C, Brooks NH. Wegener’s granulomatosis and the heart. Br Heart J 1994; 71: 82–6.

    OpenUrlAbstract/FREE Full Text
18. Schiavone WA, Ahmad M, Ockner SA. Unusual cardiac complications of Wegener’s granulomatosis. Chest 1985; 88: 745–8.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403–10.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Gross WL, Rasmussen N. Treatment of Wegener’s granulomatosis: the view from two non-nephrologists. Nephrol Dial Transplant 1994; 9: 1219–22.

    OpenUrlFREE Full Text
21. ↵
    Guillevin L, Cordier J-F, Lhote F, et al. A prospective multicenter randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997; 40: 2187–98.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective randomized study. Arthritis Rheum 1998; 41: 1835–44.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997; 90: 401–9.

    OpenUrlAbstract/FREE Full Text
24. ↵
    de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018–27.

    OpenUrlAbstract/FREE Full Text
25. ↵
    Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997; 23: 841–53.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerolonephritis. Arthritis Rheum 2000; 43: 1836–40.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757–63.

    OpenUrlPubMedWeb of Science
28. ↵
    Cole E, Cattran D, Magil A, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. Am J Kidney Dis 1992; 20: 261–9.

    OpenUrlPubMedWeb of Science
29. ↵
    Zauner I, Bach D, Braun N, et al. Predictive value of initial histology and effects of plasmaphoresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 2002; 39: 28–35.

    OpenUrlPubMedWeb of Science
30. ↵
    Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638–45.

    OpenUrlPubMedWeb of Science